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SUMMARY
SETTING—Patients who initiated treatment for multi-drug-resistant tuberculosis (MDR-TB) at 
15 Programmatic Management of Drug-resistant Tuberculosis (PMDT) health facilities in the 
Philippines between July and December 2012.
OBJECTIVES—To describe patients’ views of current interventions, and suggest changes likely 
to reduce MDR-TB loss to follow-up.
METHODS—In-depth interviews were conducted between April and July 2014 with MDR-TB 
patients who were undergoing treatment, had finished treatment at the time of the interview 
(controls), or had been lost to follow-up (LTFU). Responses were thematically analyzed.
RESULTS—Interviews were conducted with 182 patients who were undergoing or had 
completed treatment and 91 LTFU patients. Views and suggestions could be thematically 
categorized as approaches to facilitate adherence or address barriers to adherence. The top themes 
were the need for transportation assistance or improvements to the current transportation 
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assistance program, food assistance, and difficulties patients encountered related to their 
medications. These themes were addressed by respectively 63%, 60%, and 32% of the 
participants.
CONCLUSIONS—A more patient-centered approach is needed to improve MDR-TB treatment 
adherence. Programs should strive to provide assistance that considers patient preferences, is 
adequate to cover actual costs or needs, and is delivered in a timely, uninterrupted manner.
Keywords
adherence; incentives; enablers; patient-centered; qualitative study
The philippines has been designated a high burden country for multidrug-resistant 
tuberculosis (MDR-TB, defined as TB resistant to at least isoniazid and rifampin [RMP]) by 
the World Health Organization (WHO).1 In 2013, an estimated 2% of new and 21% of 
retreatment cases had MDR-TB.2 The number of patients who have initiated treatment 
through health facilities offering Programmatic Management of Drug-resistant Tuberculosis 
(PMDT) has steadily increased from its initiation in 1999.3 However, the proportion of loss 
to follow-up has also risen. In the 2010 cohort of patients treated under PMDT, 38% had a 
recorded outcome of lost to follow-up (LTFU).3
In an effort to improve MDR-TB treatment completion rates, in-depth interviews were 
conducted with patients who were enrolled on MDR-TB treatment. The aim of these 
interviews was two-fold. The first was to identify factors significantly associated with loss to 
follow-up from MDR-TB treatment. These findings have been reported elsewhere.4 The 
second aim was to describe patients’ views regarding the types and delivery of interventions 
that would have a positive impact on preventing or reducing MDR-TB treatment loss to 
follow-up. We report on data collected as part of this second aim.
METHODS
Setting/study population
We conducted a case-control study. The study source population included all adult MDR-TB 
patients and patients with RMP-resistant TB aged ≥18 years who initiated MDR-TB 
treatment according to WHO guidelines between 1 July and 31 December 2012 in the 
Philippines.4,5 Cases were defined as patients from the source population who were LTFU 
from MDR-TB treatment (i.e., patients whose treatment was interrupted for at least 2 
consecutive months) at any time during treatment. Controls were defined as patients from 
the source population who were undergoing or had finished their MDR-TB treatment at the 
time of the interview.
We included patients from the source population who received care through the 15 PMDT 
treatment centers* that had at least three drug-resistant TB patients who were LTFU and not 
known to have died by 1 January 2014. Study staff attempted to find all eligible LTFU 
patients using patient registers, and invited them to participate in the study, which included 
*At the time of this study, there were 44 PMDT centers in the country.
Tupasi et al. Page 2













an in-depth interview and consent to a review of their medical documentation. For each case 
enrolled, two controls from the same PMDT treatment facility, who had initiated treatment 
in the same quarter as the case, were randomly selected and invited to participate in the 
study.
The team that conducted the interviews and medical documentation review comprised six 
nurses and one pharmacist. Staff underwent an intensive 4-day training course, during which 
they were oriented to the protocol, the informed consent process, the interview process, and 
the interview questions. They were also taught how to pace the interview, ask probing 
questions, take field notes and document responses, and perform medical record abstraction.
Data collection
Interviews took place in participants’ homes, a treatment center, or a mutually agreed 
location. Interviews were conducted in a structured manner, using a standard interview form 
that had been field-tested. A funnel sequence of questions developed by the study 
investigators was used to solicit participant views on interventions to improve treatment 
adherence. Participants were first asked to think about their own experience and identify 
what the National Tuberculosis Program (NTP) could do to help patients adhere to 
treatment. This was followed by questions focused on specific interventions and 
implementation of these interventions. Finally, an open-ended question asked participants to 
consider the preceding discussion and identify the top ‘three things’ that would enable 
patients to remain adherent to treatment. We report participants’ responses and 
accompanying comments to this final question.
Interviews lasted approximately 90 min and were conducted in English, Tagalog, Bicolano, 
or Cebuano (the most common languages at the enrollment locations) by staff fluent in these 
languages. Responses were transcribed onto the interview forms, and translated into English 
by the same interviewer.
Data analysis
Data were entered into a Microsoft Access electronic database (Redmond, WA, USA). 
Responses to open-ended questions were exported to Microsoft Excel, and thematic analysis 
was performed.6 Themes were not imposed a priori; instead an initial list of codes was 
developed by two investigators based upon a preliminary review of the participants’ 
responses. Each participant’s response was then read independently by two of three staff, 
coded, code frequencies generated, and the results compared. Discrepancies were discussed 
and resolved.
Ethics statement
Before initiating the study, approval was obtained from the Institutional Review Board (IRB) 
of the Tropical Disease Foundation (Makati City), the Lung Center of the Philippines’ Ethics 
Review Committee (ERC) (Quezon City), and the ERC of the Philippine Tuberculosis 
Society, Inc (Quezon City, the Philip-pines). The US Centers for Disease Control and 
Prevention (CDC; Atlanta, GA, USA) determined that CDC involvement did not constitute 
engagement in human subject research, and submission to the CDC IRB was not required.
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A total of 91 cases and 182 controls from a group of 136 LFTU patients and 341 non-LTFU 
patients who were eligible for study inclusion were interviewed. As shown in Table 1, 
interview participants included 164 (60.1%) males. The mean age at treatment start was 39 
± 13 years (median 40, range 16–68). All had pulmonary TB; 97 (35%) had cavitary disease. 
Table 2 summarizes interventions to enable treatment adherence that were available to 
MDR-TB patients at the time of the study.
Participant-recommended interventions to facilitate treatment adherence
When invited to identify the top three things the NTP could do to help patients, 87 cases and 
181 controls identified one or more factors they perceived as most important. Participant 
responses were separated into two major themes, with a total of 19 subthemes.
The first theme, related to approaches for improving adherence, contained the following 14 
subthemes: 1) transportation assistance; 2) food allowance or assistance; 3) housing; 4) 
treatment centers closer to the patient’s home; 5) general financial assistance for daily 
expenses; 6) reduced treatment duration; 7) directly observed therapy (DOT) at the patient’s 
home; 8) patient and community education; 9) psychological or spiritual counseling; 10) 
assistance with medication side effects; 11) free medication (type of medication not 
specified); 12) text message reminders; 13) improved efficiency in treatment centers; and 14) 
development of a ‘livelihood’ program so patients could earn money or educational 
assistance for their children.
The second theme, which addressed barriers to treatment adherence, contained the following 
five subthemes: 1) medication factors; 2) costs associated with hospitalization or care for 
treatment toxicities; 3) staff relationships, communications, or rapport with patients; 4) 
opening hours of treatment facilities; and 5) treatment facility staff not allowing patients to 
continue or return to treatment due to past non-adherence. Figure 1 gives the percentage of 
participants who provided a response that reflected a particular theme. This figure also 
illustrates responses provided by cases and controls.
Among the factors to improve treatment adherence, transportation assistance was mentioned 
by the majority of participants (n = 168, 63%). Table 3 shows the subanalysis of 
participants’ responses related to transportation assistance. Most participants who discussed 
transportation assistance provided general comments in which they simply stated the need 
for this type of assistance (110/168, 65%). Forty-six (27%) noted a need to increase the 
amount of assistance provided to cover the full cost of transportation to and from the 
treatment facility each day. In addition, 26 (15%) participants discussed difficulties 
encountered when provision of transportation assistance is delayed or interrupted. Fourteen 
(8%) participants acknowledged that they, or other patients they knew, had used the 
transportation assistance to purchase food rather than transportation. Four (2%) participants 
expressed hope that the NTP would be able to pick patients up at their homes, take them to 
the treatment facility, and then drive them home. Another three (2%) expressed a desire to 
obtain enough transportation assistance to allow a companion to accompany them to the 
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treatment facility. These participants explained that they had become debilitated and were 
unable to travel on their own.
An allowance for food, or food assistance, was the second most common intervention 
suggested by participants (n = 161, 60%) as a means to improve adherence. Similar to the 
general comments made regarding transportation assistance, Table 3 shows that most 
participants who discussed the need for food assistance simply stated this need and did not 
expand their answers further (n = 81, 50%). Others provided specific suggestions or a 
rationale for their response. Thirty-seven (23%) participants suggested that food be provided 
at the treatment centers when patients are undergoing DOT. Some participants stated that 
food assistance would help lessen medication side effects (n = 24, 15%), while some noted 
that food assistance would help patients regain their health or weight (n =15, 9%). Five (3%) 
participants requested that patients be provided an allowance to purchase food.
The third topic addressed most often by participants was medication factors (n = 87, 32%). 
As shown in Table 3, participants’ comments tended to focus on reasons why patients did 
not want to take the medication. The majority of participant responses (n = 48, 55%) focused 
on medication side effects, or a desire for medications with fewer side effects. Some patients 
commented that fewer side effects could be achieved by taking fewer drugs. Furthermore, 41 
(47%) participants specifically requested that fewer drugs be given, or that the medication be 
changed so that it would be easier for patients to take each dose. Participants who asked for 
fewer drugs noted that the amount of medication to be ingested was overwhelming at times. 
Those requesting medication changes asked for flavoring in liquid medication, the use of 
pills rather than liquids, injections rather than pills, or the elimination of injectable 
medication because of injection pain. Sixteen (18%) participants noted the need for ‘more 
effective drugs’ that would achieve a cure in less time than the current treatment available. 
Finally, nine (10%) participants specifically requested that PASER® (para-aminosalicylic 
acid, now considered an add-on agent8) be eliminated from the treatment regimen or 
changed into another formulation, citing the medicine’s side effects and taste as reasons.
Table 4 gives representative quotes related to these top three factors and other frequently 
proposed interventions, including halfway houses (temporary housing for patients from 
remote areas), treatment centers closer to patients’ homes, DOT at home, patient and 
community education, counseling, free hospitalization or access to specialists for adverse 
drug reactions, and improved patient-provider relationships. These quotes reflect concerns 
commonly expressed by participants. When examined alongside the list of proposed 
interventions and self-reported reasons from cases for stopping treatment (Figure 2), these 
quotes provide context for patients’ decision-making, and insights into program 
improvements.
DISCUSSION
Interviews with both MDR-TB patients who remained adherent to treatment and those LTFU 
illustrate that assistance with the cost of transportation, food, and housing is essential for 
treatment adherence. The provision of food and financial assistance for transportation to and 
from a treatment center may be viewed less as an incentive used to coax a patient or a 
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reward for those who remain on treatment, and more as an enabler that facilitates adherence 
during a treatment course that otherwise depletes patients and family members physically, 
financially, and mentally.9–12 Moreover, if the application process for financial assistance is 
long and difficult, if this assistance is not given in a timely manner, or if delivery of 
assistance is interrupted, patients are likely to abandon their efforts to adhere to treatment.
The time between the start of treatment and the provision of initial assistance requires 
careful consideration. A patient’s lack of resources can hamper treatment adherence 
immediately. Reports in the literature indicate that some TB patients expend their limited 
resources while pursuing a diagnosis.13,14 Furthermore, missed doses early in the course of 
treatment can become self-defeating for the patient15 and create an unfavorable impression 
of the patient among care givers. An efficient process is therefore needed to register patients 
into an assistance program, deliver initial help, and institute safeguards to avoid exploitation 
of available assistance.16–19
A little over a third of participants (32%) noted medication factors as barriers to adherence. 
While the quantity and format in which medications are delivered (e.g., injection or tablets) 
are not easily modified, the provision of care and treatment to help patients cope with 
medication side effects is within the purview of PMDT. This can reduce the number of 
patients compelled to make a conscious decision to miss doses or abandon treatment because 
they are unable to engage in instrumental activities of daily living (e.g., work, use of public 
transportation, housekeeping, meal preparation), or withhold reporting on side effects they 
are experiencing due to concerns regarding the cost of care or treatment for these problems.
As reported elsewhere, incentives and enablers are not a substitute for a strong patient-
provider relationship based upon trust, mutual respect, and effective communication.20 Our 
findings reinforce this perspective given the participants’ endorsement of interventions 
centered on counseling, patient or community education, and staff relationships.21–24 
Provider interventions focused on establishing patient trust and respect may address active 
listening, respectful feedback, empathy, health literacy, message-framing, and motivational 
interviewing.25–27
Finally, current LTFU rates in the Philippines and the results of this study highlight the need 
to assess the benefits and drawbacks of clinic-based DOT vs. home-based DOT.28,29 A 
number of cases indicated that home-based DOT would have been helpful. Furthermore, 
some study participants directly attributed their default from treatment to the costs 
associated with going to the clinic each day. Given that the majority of participants live 
below the poverty level, it is unlikely they overstated their situation, nor is their situation 
unique. In a study of unaccounted costs of anti-tuberculosis treatment, Guzman-Montes et 
al. reported that clinic-based DOT contributed disproportionately to the costs incurred by 
patients.30 The programmatic costs of home-based DOT thus need to be weighed against the 
costs incurred if the incidence of MDR-TB continues to increase in the Philippines.
Our study is subject to several limitations. First, some cases and eligible controls could not 
be located; these patients’ responses could be substantially different from those of persons 
who were less mobile and easily located. Participants’ responses may reflect socially 
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desirable answers rather than their true thoughts and experiences. The quality of the data 
collected depended on the interviewers’ skills, and was subject to the use of field notes 
rather than audio recordings to capture responses as well as interviewer bias. To minimize 
this, interviewers received training in taking and transcribing field notes, bias, the influence 
of verbal and non-verbal communications, and how best to obtain candid responses. 
Furthermore, the analysis of participant responses can be interpretative; for this reason, 
themes and coding were performed independently by two researchers, then compared and 
reconciled. Finally, the retrospective design of this study is subject to recall bias.
Despite these limitations, this study provides important data for designing interventions to 
reduce loss to follow-up during MDR-TB treatment in the Philippines. Further evaluation is 
needed to determine if interventions developed based upon these data positively influence 
treatment completion. Evaluation of these interventions must assess fidelity to the 
intervention design. A cost analysis of these interventions would also be beneficial.
CONCLUSIONS
A revision of the PMDT strategy should address the identified barriers to MDR-TB 
treatment completion. Our findings highlight the need for a more patient-centered approach, 
including the provision of sufficient and timely assistance to patients, optimized care for 
treatment side effects, cultivation of patient-provider relationships through improved 
communication, and community-based DOT.
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Adherence barriers and enablers to improve treatment adherence as suggested by study 
participants (n =268). *A barrier to treatment adherence. †An enabler to improve treatment 
adherence. DOT = directly observed therapy.
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Self-reported reasons for stopping treatment among persons lost to follow-up (n = 89*). 
Figure summarizes the results of qualitative analysis of answer on the question: ‘All of the 
questions I have asked address reasons why many people stop taking treatment before being 
advised to stop by their doctors. What were the main reasons you stopped taking your 
treatment early?’ *Of 91 cases, 1 person did not provide an answer and 1 person was 
initially categorized as a control but was a case. He was interviewed using a ‘control’ form, 
which did not contain this question, totaling 89 patients who responded to this question.
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All participants (n = 273)
n (%)
Persons lost to follow-up 




(controls) (n = 182)
n (%)
Sex
 Male 164 (60.1) 60 (65.9) 104 (57.1)
 Female 109 (39.9) 31 (34.1) 78 (42.9)
Age, years
 <20 12 (4.4) 4 (4.4) 8 (4.4)
 20–29 68 (24.9) 18 (19.8) 50 (27.5)
 30–39 55 (20.1) 15 (16.5) 40 (21.9)
 40–49 77 (28.2) 31 (34.1) 46 (25.3)
 50–59 42 (15.4) 13 (14.3) 29 (16.0)
 ≥60 19 (7.0) 10 (10.9) 9 (4.9)
Civil status
 Single, separated, widowed 109 (39.9) 42 (46.2) 67 (36.8)
 Married, living together 164 (60.1) 49 (53.8) 115 (63.2)
Employment status
 Unemployed 96 (35.2) 33 (46.5) 63 (51.2)
 Employed 98 (35.9) 38 (53.5) 60 (48.8)
 Other (retired, student, disabled, housewife) 43 (15.8) 12 (24) 31 (34.1)
 Unknown 36 (13.1) 8 (17.4) 28 (31.8)
Education
 No formal schooling/elementary/high school 197 (72.2) 67 (73.6) 130 (71.4)
 College/graduate school 75 (27.5) 24 (26.4) 51 (28.0)
 Unknown 1 (0.3) 0 1 (0.6)
Socio-economic class*
 Category C: living at or below the poverty line 250 (91.6) 85 (93.4) 165 (91.2)
 Category A and B: living above the poverty line 22 (8.0) 6 (6.6) 16 (8.8)
 Unknown 1 (0.4) 0 1 (0.5)
Residence
 Rural area 40 (14.6) 15 (16.5) 25 (13.7)
 Urban slum 126 (46.2) 49 (53.8) 77 (42.3)
 Urban area 105 (38.5) 26 (28.6) 79 (43.4)
 Unknown 2 (0.7) 1 (1.1) 1 (0.6)
HIV test result
 Missing (HIV test not done/missing) 217 (79.5) 86 (94.5) 131 (72.0)
 Positive 2 (0.7) 1 (1.1) 1 (0.5)
 Negative 51 (18.7) 2 (2.2) 49 (27.0)
 HIV test done, but result not recorded 3 (1.1) 2 (2.2) 1 (0.5)
Site of disease
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Characteristics
All participants (n = 273)
n (%)
Persons lost to follow-up 




(controls) (n = 182)
n (%)
 Pulmonary 273 (100) 91 (33.3) 182 (66.7)
 Extra-pulmonary 0 (0) 0 (0) 0 (0)
Cavity on baseline chest X-ray reading
 Yes 97 (35.5) 31 (34.1) 66 (36.3)
 No 134 (49.1) 39 (42.8) 95 (52.2)
 Unknown 42 (15.4) 21 (23.1) 21 (11.5)
*
Living at or below the poverty line is defined as per capita income of 16 841 Philippine Peso a year.7
HIV = human immunodeficiency virus.
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Table 2
Program services to enable treatment adherence available to MDR-TB patients at the time of this study
Anti-tuberculosis medicines provided to patients at no cost
Medications to manage adverse events provided to patients at no cost (limited formulary)
TB diagnostic tests provided to patients at no cost
Fixed amount provided for transportation costs (funds provided retrospectively, based upon adherence to appointments)
Food basket incentives (limited availability)
Temporary housing located near PMDT treatment centers for patients from rural areas (limited availability)
44 PMDT treatment centers located throughout the country to provide comprehensive MDR-TB services
Patient education (non-standardized)
Patient support groups (located within some facilities)
Small monetary bonus provided to patients at month 6, 12, and 18 months, if fully adherent during each 6-month period
MDR-TB = multidrug-resistant tuberculosis; PMDT = programmatic management of drug-resistant tuberculosis.
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Table 3
Thematic analysis of participants’ responses focusing on transportation and food assistance as enablers, and 
medication factors as barriers to treatment adherence
Topic and response themes
Percentage of participants whose responses reflected 
each theme
All participants (n 
= 168)
%
Cases (n = 50)
%




 Participant made a general comment regarding the need for transportation 
allowance
65 70 64
 Need to increase the current transportation allowance, or provide sufficient 
amount to cover transportation costs noted
27 16 32
 Delays receiving transportation allowance or interruptions in the provision of 
the transportation allowance reported
15 12 17
 Participant acknowledged that they, or someone they knew, used the 
transportation allowance to purchase food
8 10 8
 TB program-sponsored transportation that would pick up and return patients 
to their homes suggested
2 6 1
 Request for expanded transportation allowance so that a companion could 
accompany a patient during treatment
2 2 2
Food assistance (n = 161) (n = 55) (n = 106)
 Participant made a general comment regarding the need for food assistance 50 53 49
 Request for food to be provided at the time of DOT 23 18 25
 Need for food assistance to lessen medication side effects noted 15 16 14
 Need for food assistance to strengthen patients or enable patients to regain 
weight or health noted
9 16 6
 Request for an allowance to purchase food 3 4 3
Medication factors (n = 87) (n = 35) (n = 52)
 Request for better medication with fewer side effects (some patients noted 
that fewer side effects could be achieved by taking fewer drugs)
55 51 58
 Request for less or fewer drugs, or changes in the medications (i.e., flavor, 
change liquid to a pill), to make it easier to take each dose
47 34 56
 Request for ‘more effective’ drugs to achieve cure in less time 18 20 17
 Request to change or eliminate ‘PASER’ (para-aminosalicylic acid) 10 14 8
TB = tuberculosis; DOT = directly observed therapy.

















 I am receiving 50 pesos per day allowance from the center, but it is not enough and sometimes delayed. I am spending 100 pesos every day 
for my tricycle fare, so I always fill in the balance of 50 pesos. Sometimes there is a delay in depositing the money. That is why sometimes I 
borrow from my neighbors. If they let me borrow, I go to the center. If not, I just stay home. (Male, 47 years old, LTFU)
 Another big help for me is transportation assistance. Though I am already receiving it, still it does not help a lot because it is less than my 
actual transportation fare. Maybe it would help if they adjust the amount to the actual fare. If this is so, I will not have any more reason not to go 
to the center and take my medication. (Female, 52 years old, undergoing treatment at time of interview)
Food assistance
 It would be good if there is food in the center because sometimes we don’t have food at home. It will be a big help, not only for me, but for 
other patients as well. With this, I don’t need to worry about what to eat, or if there is something to eat. Sometimes also, I felt less side effects 
when my stomach is not empty. This is also the one thing to encourage the patients to go to the center. Besides, we don’t have to spend the 
transportation allowance to buy food. (Female, 18 years old, undergoing treatment at time of interview)
 I would like to receive, if it is not too much to ask, food so that it will not be too difficult to take medication. Besides, it will lessen the 
adverse effects, especially stomach upset. Also, if there is food daily, I am assured that I have something to eat before or after taking my 
medication. (Male, 23 years old, LTFU)
Medication factors/treatment duration
 Though I know that the minimum duration of treatment is 18 months, I still wish that it can be shortened. I am so eager to work so that my 
family may have something to eat, but I cannot do it if I am still on treatment. I cannot afford to work [and] at the same time, take medications 
because of so many side effects. So I have to choose treatment over work because I am sick. But it troubles me a lot to see my mother doing 
everything for us to survive the day. I wish that I am already done with my treatment so that I could help her. (Male, 35 years old, undergoing 
treatment at time of interview)
 Treatment of MDR-TB is very complicated. The medications are also complicated. It has to be a combination of drugs and injections and 
there is nothing I can do but take them. But if I have a choice, I choose not to drink PASER (para-aminosalicylic acid). The mere sight of 
PASER made me vomit. There were times that I was walking and I thought of not going to the center instead. I would have my body ran [over] 
by a bus. I wanted to commit suicide. I just thought of my family. That’s why I did not do it. (Male, 57 years old, undergoing treatment at time 
of interview)
Housing
 Another thing that would help is the provision of halfway house. I have already availed this benefit and I can testify that this is a big factor 
why I am able to finish my intensive phase…. If I were not in-housed, I might not be able to finish my treatment. There are many side effects 
that I had experienced. There was a time when I was not able to get up and walk due to joint pain. The people there helped me get through and I 
was thankful that I didn’t need to travel. Being in-housed was great, but the only thing that I want to suggest is provide food, enough food for 
the patient. (Male, 29 years old, undergoing treatment at time of interview)
 Another thing that would help is provide a halfway house near the treatment center. This will be more convenient for us who live far from the 
center … and I can take my medication even if it’s raining. When it rains it floods in our community because the area is very low, and this 
caused me to be absent. (Female, 29 years old, undergoing treatment at time of interview)
 If the government will open half-way home for the patient. This will protect the family of the patient to be infected. Then, if the patient [is 
sputum smear] negative, he has to leave the shelter so that new patients can live there also. (Male, 44 years old, undergoing treatment at time of 
interview)
Treatment centers closer to home
 I had difficulty going to the center every day because of lack of money for transportation. Also, I need to wake up earlier because I have to 
travel 1 to 1½ hours to get there. I started having absences and eventually stopped. If there is a treatment center near my house, there will be no 
problem going there. I should have finished my treatment if there [was] one near my place. (Male, 25 years old, LTFU)
 I would like to have a treatment center near my house. There are so many patients who need treatment but there is no treatment facility in the 
area. If the center is near my house, I don’t have to travel far. I am so weak and can’t travel anymore. I know that there [are] lots of patients out 
there like me. Another benefit is that aside from the short distance, I don’t need to spend a lot for transportation. (Male, 31 years old, LTFU)
Direct observed therapy at home
 Though there is a health center near my house, I still want my medication to be taken at home. If ever there are adverse events, especially 
vomiting, I can easily go to my room and vomit there. At least I’m already at the comfort of my home and avoid embarrassment. (Male, 44 
years old, undergoing treatment at time of interview)
 I can’t see anymore. I need to have a companion to be able to go to the center and I can’t rely on my children to go with me because they have 
jobs … It would be best if somebody will bring my medication to my house. I won’t have to go out and bother my children or my son-in-law 
bringing and fetching me to and from the treatment center. (Female, 60 years old, LTFU)
Patient/community education
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 My number one [suggestion] is health education because I think it is what every individual should receive. It is very important that I know my 
sickness, what should I do to be cured, who should I talk to, and where can I go to get the right treatment. (Male, 30 years old, undergoing 
treatment at time of interview)
Psychological or spiritual counseling
 Psychological counseling is very important because we, patients, are experiencing dilemma and anxiety. We are torn between the treatment 
and coping with the side effects of the medication, besides, facing the future with uncertainty. For me, I would always ask myself, what happens 
next? … Sometimes, I would think of quitting, especially when I experienced the pain due to uric acid elevation. I could no longer walk. But 
then again, I would think of my disease and my family. Talking to a counselor is a great help because I am able to release my unexpressed 
thoughts and get enlightenment. (Male, 28 years old, undergoing treatment at time of interview)
 Losing a husband while I am sick is very devastating. I started experiencing depression and self-pity which made me feel more ill. This is the 
main reason why I quit treatment, because I felt that my life is already worthless so I wanted to die also. But as the days pass by, I realized I 
should not be selfish. I should consider my children, though they are already married, and my grandchildren whom I am really fond of. I wanted 
to become strong for them, but how? That is why I really need to talk to a professional counselor, because I know that he could help me through 
my depression. (Female, 48 years old, LTFU)
Free hospitalization or access to specialists for adverse drug reactions
 Another thing that would help is the provision of free hospitalization and surgery. Sometimes, I don’t tell [the doctors and nurses] what I 
really feel because I am afraid that I will be hospitalized. It is very expensive and I don’t have money for it. But if it is provided, I will not need 
to hide what I really feel [medication side effects] because I know that I won’t have to pay for the hospitalization should there be a need. (Male, 
24 years old, undergoing treatment at time of interview)
 There are government hospitals which accommodate indigent patient[s]. The problem is they do not have medicines. They just give us 
prescriptions so that we may buy them [prescribed medications] from the outside. (Female, 52 years old, undergoing treatment at time of 
interview)
Improved staff relationships, communications, or rapport with patients
 Train health staff more when it comes to knowledge, especially psychologically. Some staff are not accommodating and not approachable. 
(Male, 47 years old, undergoing treatment at time of interview)
 Make sure that staff will be trained so that they will not despise patients. Patients might get fed up if this continues. (Male, 46 years old, 
undergoing treatment at time of interview)
 Treating patients better will alleviate patients feeling of depression. (Female, 19 years old, undergoing treatment at time of interview)
 The nurses are not accommodating. They scold the patients and hurt our feelings. (Female, 39 years old, LTFU)
LTFU = lost to follow-up; MDR-TB = multidrug-resistant tuberculosis.
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